Quarter Comparison
Revenue
Operating Income
Gross Margin
Net Margin
Income Statement
Balance Sheet
Earnings Release
EX-99.1 2 fbio-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to
EX-99.1 2 fbio-20260813xex99d1.htm EX-99.1 Exhibit 99.1 Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025 Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO ® and UNLOXCYT ™ Miami, FL – August 13, 2026 – Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced financial results and recent corporate highlights for...
Source
Exhibit EX-99.1
0001104659-26-095931
Filed August 13, 2026 at 8:15 PM UTC. The figures above are from the audited statements, not from this release.